Context Therapeutics (CNTX)
NASDAQ:CNTX
Want to see CNTX full AI Analyst Report?
CNTX Stock Chart & Stats
$2.43
$0.09(8.26%)
At close: 4:00 PM EST
$2.43
$0.09(8.26%)
Day’s Range― - ―
52-Week Range$0.49 - $3.62
Previous CloseN/A
Volume293.07K
Average Volume (3M)830.13K
Market Cap
$230.62M
Enterprise Value$157.38M
Total Cash (Recent Filing)$66.00M
Total Debt (Recent Filing)$112.06K
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 13, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding91,879,170
10 Day Avg. Volume775,845
30 Day Avg. Volume830,128
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.33K
Enterprise Value/Ebitda-4.06
Forecast
1Y Price Target
$5.43Price Target Upside123.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressAdvancement of multiple bispecific T-cell engager programs toward initial human trials creates several opportunities for clinical readouts that could validate the platform.
Early Efficacy And TolerabilityA confirmed partial response in a heavily pre-treated ovarian cancer patient together with limited serious immune-related safety events suggests early signs of efficacy at tolerable dose levels.
Regulatory DesignationFast Track designation for the lead CLDN6-targeting candidate supports an expedited development pathway and may reduce regulatory risk around planned clinical milestones.
Bears Say
Financial RunwayAvailable cash appears limited relative to current spending, creating a need for additional financing that could dilute existing shareholders.
Safety And Dose InterruptionsHigher-than-expected drug exposures led to dose adjustments and a pause in a higher-dose cohort, highlighting unresolved safety and tolerability risks for the programs.
Target-related Off-tumor ToxicityExpression of the Nectin-4 target in healthy tissues has been linked to skin-related toxicities with similar therapies, raising target-specific safety concerns for comparable approaches.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.49 and its highest was $3.62 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $230.62M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 23 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Mar 23, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.105 by -$0.035.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.105. Following the earnings report the stock price went up 5.298%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.43 (123.52% Upside)
$5.43 (123.52% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 19.0%
Last 30 Days ▲ 19.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
188.25%
12-Months-Change
Fundamentals
Return on Equity
-47.04%
Trailing 12-Months
Asset Growth
-30.20%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$5.43
▲(123.52% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
5.87% Mutual Funds
53.70% Other Institutional Investors
35.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---